Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
- Design
- Meta-analysis · 60080 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationAll included trials enrolled people with type 2 diabetes.
- Could weight loss explain it?
- PossiblyNo heterogeneity by BMI subgroup, which argues against strong dependence on baseline adiposity; mediation by weight change not analysed.
- Study tier
- Study tier 1Systematic meta-analysis of large randomized outcome trials with consistent effects.
- Assessment
- Version 2 · curated · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
Pooling eight cardiovascular outcome trials in 60,080 people with type 2 diabetes, GLP-1 receptor agonists reduced major cardiovascular events by 14%, death by 12%, and kidney outcomes by 21%, with no increase in pancreatitis, pancreatic cancer or retinopathy overall. Applies to diabetes populations.
01Findings
What the study reported
- Drugs
- Liraglutide, Semaglutide, Dulaglutide, Exenatide, Lixisenatide, Albiglutide, Efpeglenatide
- Comparator
- placebo
- Primary outcome
- MACE across 8 placebo-controlled CVOTs (60,080 patients with T2D)
- Effect
- MACE HR 0.86; all-cause mortality HR 0.88; HF admission HR 0.89; composite kidney HR 0.79
- 95% confidence interval
- 0.80 to 0.93 (MACE)
- P value
- <0.0001
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Diabetes status
- type 2 diabetes (all included trials)
- Cvd status
- cardiovascular disease present in population (see abstract)
- Sample size
- 500
Study quality details
- Study design
- Meta-analysis
- Sample size
- 500
- Randomization
- n/a
- Blinding
- not stated
- Comparator
- placebo
- Follow up duration
- not stated
- Outcome type
- mixed
- Replication
- 8 trials, no significant heterogeneity
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI 0·80-0·93]
- Risk of bias
- trial-level; all industry-sponsored trials
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- No specific funding stated in abstract; authors report industry consulting
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- Independent academic meta-analysis of manufacturer-sponsored trials.
- Author conflicts
- Lead author reports consulting for Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi and others.
- Independent replication
- yes (multiple independent meta-analyses reach similar estimates)
- Notes
- Authors declare relationships with the drug's manufacturer: AstraZeneca (originally Amylin/Eli Lilly)
Funding is shown on every study and never used to score it.
03Claims
Claims this study bears on
- The cardiovascular benefit of GLP-1 receptor agonists is not explained by weight loss.Supports
Meta-analysis of 8 CVOTs in T2D: MACE HR 0.86 with modest weight loss.
- GLP-1 receptor agonists slow biological aging or extend healthspan in humans.Mixed
All-cause mortality HR 0.88 in T2D CVOTs; high-risk populations only.
04Source
The source, as retrieved
Abstract
[BACKGROUND] GLP-1 receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes. However, uncertainty regarding kidney outcomes persists and whether benefits extend to exendin-4-based GLP-1 receptor remains uncertain. We aimed to meta-analyse the most up-to-date evidence on the cardiovascular benefits and risks of GLP-1 receptor agonists from outcome trials in patients with type 2 diabetes. [METHODS] We did a meta-analysis, including new data from AMPLITUDE-O, using a random effects model to estimate overall hazard ratio (HR) for MACE; its components; all-cause mortality; hospital admission for heart failure; a composite kidney outcome consisting of development of macroalbuminuria, doubling of serum creatinine, or at least 40% decline in estimated glomerular filtration rate (eGFR), kidney replacement therapy, or death due to kidney disease; worsening of kidney function, based on eGFR change; and odds ratios for key safety outcomes (severe hypoglycaemia, retinopathy, pancreatitis, and pancreatic cancer). We also examined MACE outcome in patient subgroups on the basis of MACE incidence rates in the placebo group, presence or absence of cardiovascular disease, HbA1c level, trial duration, treatment dosing interval, structural homology to human GLP-1 or exendin-4, BMI, age, and eGFR. We searched PubMed for eligible trials reporting MACE (ie, cardiovascular death, myocardial infarction, or stroke), up to June 9, 2021. We meta-analysed data from published randomised placebo-controlled trials testing either injectable or oral GLP-1 receptor agonists in patients with type 2 diabetes. We restricted the search to trials of more than 500 patients with a primary outcome that included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. This meta-analysis was registered on PROSPERO, CRD42021259711. [FINDINGS] Of 98 articles screened, eight trials comprising 60 080 patients fulfilled the prespecified criteria and were included. Overall, GLP-1 receptor agonists reduced MACE by 14% (HR 0·86 [95% CI 0·80-0·93]; p<0·0001), with no significant heterogeneity across GLP-1 receptor agonist structural homology or eight other examined subgroups (all pinteraction≥0·14). GLP-1 receptor agonists reduced all-cause mortality by 12% (HR 0·88 [95% CI 0·82-0·94]; p=0·0001), hospital admission for heart failure by 11% (HR 0·89 [95% CI 0·82-0·98]; p=0·013), and the composite kidney outcome by 21% (HR 0·79 [95% CI 0·73-0·87]; p<0·0001), with no increase in risk of severe hypoglycaemia, retinopathy, or pancreatic adverse effects. In sensitivity analyses removing the only trial restricted to patients with an acute coronary syndrome (ELIXA), all benefits marginally increased, including the outcome of worsening of kidney function, based on eGFR change (HR 0·82 [95% CI 0·69-0·98]; p=0·030). [INTERPRETATION] GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes. [FUNDING] None.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 34425083 first ingestion |